SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.
about
Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient miceAnti-angiogenic therapies for metastatic colorectal cancer: current and future perspectivesTargeting tumor-stromal interactions in bone metastasisPrimary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumorThe outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendationsMulticenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.Sunitinib malate for the treatment of solid tumours: a review of current clinical data.Therapeutic effects of anti-CD115 monoclonal antibody in mouse cancer models through dual inhibition of tumor-associated macrophages and osteoclasts.A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancerFirst-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study.A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.Treatment of a GIST patient with modified dose of sunitinib by measurement of plasma drug concentrations.Phase II open-label study of sunitinib in patients with advanced breast cancer.Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents.Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis.Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells.Arterial colony stimulating factor-1 influences atherosclerotic lesions by regulating monocyte migration and apoptosis.An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer.Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation studyDynamic contrast-enhanced magnetic resonance imaging of sunitinib-induced vascular changes to schedule chemotherapy in renal cell carcinoma xenograft tumors.Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580.M-CSF mediates TNF-induced inflammatory osteolysisHistopathology and biochemistry analysis of the interaction between sunitinib and paracetamol in mice.A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells.A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.Triple-negative breast cancer.A phase I study of sunitinib plus capecitabine in patients with advanced solid tumorsMusculoskeletal molecular imaging: a comprehensive overview.Preclinical evaluation of sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastasesRenal cell carcinoma bone metastases: clinical advancesEfficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience.Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance.Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failureSunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II studyMechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.
P2860
Q24810598-FDD7C6F7-B119-43BC-BA41-6A8D8922B879Q26826817-CBA84E10-229B-4616-B7F0-EA1DE5940D40Q27024561-A2B01694-892C-479F-9215-B44BF1AF4603Q27851455-DEE4E952-23D7-4433-95CC-1A4C3DE38E4EQ27851744-004784DE-4070-4B16-82D9-EB0961682278Q28247449-FE15DC08-CA02-4184-972D-4F82977332EAQ30422736-01A30799-5004-4D44-8CBF-2E4811A6EF0FQ31037756-51DC084A-BD96-46B1-8117-F64E8410C23AQ31137466-D91E4426-EB7B-4D8B-9FE5-718BB42FCBD4Q33397590-B45C2505-CB26-42F2-9040-DB28F839D639Q33400952-4CB6DAA7-4AF8-4684-901B-49FB2273BC8AQ33401396-943AA6E9-1F9D-40BA-8AB0-E1D04342F4C2Q33403257-01816280-13A5-474A-B607-04605261E714Q33403848-4BDE17E2-F62B-4E16-A6A0-5937BA3E9E21Q33409913-EEB21B8D-A089-48C0-8C9B-BBC456F2C509Q33411581-F19EC1FC-7139-46A7-AF30-A75C629EE8BEQ33565239-7ECCA2C4-98BE-4243-BB7D-40DAB385C8A3Q33613666-A7CD4FAA-CB5E-4128-99F6-8B4D3B781A11Q33648995-1E5F11EE-6EAA-44CB-BFBF-C2E3D15371E2Q33723668-4A636875-BCBE-426E-BA5E-91613AD2C3EEQ33726477-A9181B7A-3B3D-4DDD-A23F-003E617D7E25Q33902070-1B2255D4-D330-4A0C-BAF7-C436248BB7E0Q33932531-E4DF3B36-61E9-4DCF-BCD5-049BB97C0154Q33996608-6C7B0282-A59E-4CEB-842D-CFD65AA8B074Q34111200-ED4B84A0-5621-479B-A77E-7AB73A36274EQ34115782-5336CB62-ABE0-4094-920E-3CE87B499434Q34133595-CEA2F81E-FD19-46BA-BD60-538DF4B8722BQ34246117-00F71475-84D6-466C-BEBB-E4CC57E5F419Q34248681-54AA2F64-65C7-4434-9418-2B8AB85ADB9EQ34250125-ABDE0C80-2A46-4126-83DF-9A6FAAA127BBQ34274939-6D4FD482-5A97-4272-BB5E-CC52B3444BFAQ34334959-33B254E9-E350-4182-9B5D-FA7FE85A7861Q34473019-031BFE75-EE81-4644-8E86-3E9E5F968EF9Q34561406-F4254047-D757-4C1D-9E6E-4B7876C2359DQ34631216-FB47E7BC-A71B-4DB9-9576-2E010E62BA59Q34656707-271A10A1-5280-4BC7-8459-91731E63A712Q34884647-0454A842-B0CC-43A6-8990-BFF53B8497FAQ35001643-29353ED9-20DB-489F-B297-AD0A79D1546AQ35114038-0AC1B778-59BC-471B-AC14-6A7F2CBB57A8Q35184195-DF0CEFF1-1975-4DF5-BDD2-CDD5FD1C0B16
P2860
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
SU11248 inhibits tumor growth ...... cancer bone metastasis model.
@en
SU11248 inhibits tumor growth ...... cancer bone metastasis model.
@nl
type
label
SU11248 inhibits tumor growth ...... cancer bone metastasis model.
@en
SU11248 inhibits tumor growth ...... cancer bone metastasis model.
@nl
prefLabel
SU11248 inhibits tumor growth ...... cancer bone metastasis model.
@en
SU11248 inhibits tumor growth ...... cancer bone metastasis model.
@nl
P2093
P1476
SU11248 inhibits tumor growth ...... cancer bone metastasis model.
@en
P2093
Anne Marie O'Farrell
Jacqueline A Brassard
Julie M Cherrington
Kelly R Long
Lesley J Murray
Lisa M Olson
Nancy K Pryer
Paul K Keast
Theresa J Ngai
Tinya J Abrams
P304
P356
10.1023/B:CLIN.0000006873.65590.68
P577
2003-01-01T00:00:00Z
P6179
1020033628